Sanofi has announced they are discontinuing their Renassist Patient Assistance Program effective December 31, 2017, with the last day to apply being December 1.  Patients currently enrolled in the program will receive their final shipment of free Renvela before the end of the year.

Questions? Call Sanofi customer service at 1-800-633-1610 option 7, option 4.

Through a partnership with Sanofi Renal/Genzyme Corporation, Renvela® (sevelamer carbonate) and IV formulations of Hectorol® (doxercalciferol) injection are available to financially qualified dialysis patients who have no prescription drug coverage. Eligible patients may receive up to a three-month supply and if necessary, may reapply at the end of their grant period.

The American Kidney Fund administers Sanofi Renal/Genzyme’s Renal Patient Assistance Program. Assistance is made possible by a generous product donation from Sanofi Renal/Genzyme.

One application allows you to apply for Renvela® or Hectorol® Product. Applications are accepted on a rolling basis, throughout the year.

Please click the link below for Sanofi's Renassist Application Assistant:

Renvela® (sevelamer carbonate)

Prescribing information

Renvela® (sevelamer carbonate) is used to control phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Important Safety Information for Renvela

  • Do not use Renvela if you have a history of bowel obstruction.
  • Talk to your doctor if you have had difficulty swallowing or swallowing disorders; or if you have had digestive tract surgery or other digestive disorders, including severe constipation.
  • The most frequently occurring side effects with Renvela tablets include nausea and vomiting.
  • Side effects with Renvela powder taken three times a day are similar to those reported for Renvela tablets.
  • The most common side effects with sevelamer include vomiting, nausea, diarrhea, indigestion, abdominal pain, flatulence, and constipation.
  • Cases of itching, rash, fecal impaction and, less commonly, slow bowel activity, bowel obstruction, and bowel perforation have been reported.
  • Uncommon cases of difficulty swallowing the Renvela tablet have been reported. Talk to your doctor if you have difficulty swallowing medicines in tablet form. Renvela for oral suspension may be considered by your doctor if you have a history of difficulty swallowing.
  • Your doctor should monitor your bicarbonate and chloride blood levels.
  • Reduced vitamins D, E, and K (clotting factors) and folic acid blood levels may be followed by your doctor.
  • Talk to your doctor when taking Renvela with other medications.
  • Promptly contact your doctor if you experience severe abdominal pain, new or worsening constipation, or other severe intestinal symptoms while on Renvela.
  • Take Renvela with meals and adhere to your prescribed diet

Hectorol® (doxercalciferol) injection

Prescribing information

Hectorol Injection is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.

Important Safety Information for Hectorol (doxercalciferol) injection

  • You should not take Hectorol if you have a history of abnormally high calcium blood levels (hypercalcemia) or if you have very high vitamin D levels.
  • Overdosage of any form of vitamin D is dangerous and may require emergency attention.
  • Before taking Hectorol, tell your doctor if you have ever had an irregular heartbeat or seizure, or if you are taking any digitalis drugs.
  • Do not take other vitamin D related drugs if you are currently taking Hectorol.
  • It is important for anyone taking Hectorol to talk to their doctor before taking any non-prescription drugs or magnesium-containing antacids, supplements and herbal preparations and to adhere to instructions about following a low phosphorus diet and calcium supplementation.
  • Your doctor should monitor your calcium, phosphorus and PTH levels.
  • Tell your doctor if you experience symptoms of hypercalcemia such as weakness, headache, drowsiness, nausea, vomiting, dry mouth, constipation, muscle pain, bone pain, metallic taste and loss of appetite.
  • The main side effects of treatment with Hectorol are hypercalcemia, hyperphosphatemia, and oversuppression of PTH. Your doctor may ask you questions to see if you are experiencing any symptoms related to these conditions.
  • During treatment, your doctor may change your dose of Hectorol as well as the dose of your phosphate binder.
  • Common side effects seen in Hectorol-treated patients on dialysis were swelling, headache, ill feeling, nausea/vomiting, dizziness, shortness of breath, itching and slow heartbeat.
  • Tell your doctor if you are pregnant or nursing.
  • This drug should be used with caution if you have impaired liver function.

Please contact the American Kidney Fund at 1.800.795.3226 if you have any questions.

Additionally, Renassist Case Managers are available to answer questions and provide support for insured patients at 1.800.847.0069.